Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics (LPTX)
:LPTX
LPTX Stock Chart & Stats
$0.52
-$0.03(-0.86%)
At close: 4:00 PM EST
$0.52
-$0.03(-0.86%)
Day’s Range― - ―
52-Week Range$0.22 - $4.24
Previous CloseN/A
Volume72.74K
Average Volume (3M)5.70M
Market Cap
$27.09M
Enterprise Value-$5.54M
Total Cash (Recent Filing)$18.13M
Total Debt (Recent Filing)$39.00K
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Nov 17, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding56,651,840
10 Day Avg. Volume1,512,559
30 Day Avg. Volume5,700,551
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.20
Enterprise Value/Revenue-554.10
Enterprise Value/Gross Profit-1.11K
Enterprise Value/Ebitda0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPromising efficacy data point to market potential of DNK-01 in approximately 25%-50% of 2L patients.
Financial StabilityThe company reported approximately $47M in cash and cash equivalents at the end of 4Q24, which is believed to be sufficient to fund operations.
Bears Say
Pipeline DevelopmentUncertainties regarding the company's pipeline development and lack of meaningful catalysts contribute to the Neutral rating on LPTX.
Strategic PartnershipsThe company still needs to identify a partner to run the registrational Phase 3 study.
Leap Therapeutics News
LPTX FAQ
What was Leap Therapeutics’s price range in the past 12 months?
Leap Therapeutics lowest stock price was $0.22 and its highest was $4.24 in the past 12 months.
What is Leap Therapeutics’s market cap?
Leap Therapeutics’s market cap is $27.09M.
When is Leap Therapeutics’s upcoming earnings report date?
Leap Therapeutics’s upcoming earnings report date is Nov 17, 2025 which is in 17 days.
How were Leap Therapeutics’s earnings last quarter?
Leap Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.11.
Is Leap Therapeutics overvalued?
According to Wall Street analysts Leap Therapeutics’s price is currently Overvalued.
Does Leap Therapeutics pay dividends?
Leap Therapeutics does not currently pay dividends.
What is Leap Therapeutics’s EPS estimate?
Leap Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Leap Therapeutics have?
Leap Therapeutics has 56,651,840 shares outstanding.
What happened to Leap Therapeutics’s price movement after its last earnings report?
Leap Therapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -29.412%.
Which hedge fund is a major shareholder of Leap Therapeutics?
Currently, no hedge funds are holding shares in LPTX
Company Description
Leap Therapeutics
Leap Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. The company operates in the biopharmaceutical sector, specializing in the research and development of novel therapeutics aimed at treating various types of cancer. Leap Therapeutics is dedicated to advancing its lead product candidates, which target key pathways in cancer biology to provide new treatment options for patients.
Technical Analysis
Imunon
―
XTL Biopharmaceuticals Sponsored ADR
―
Carisma Therapeutics
―
MetaVia
―
Allarity Therapeutics
―
Ownership Overview
6.11% Insiders
3.49% Mutual Funds
0.33% Other Institutional Investors
85.13% Public Companies and
Individual Investors